Charles River Laboratories Surges on Record Q4 Earnings Amid Steady Demand for Drug Development Services

Charles River Laboratories International (CRL) posted a robust fourth-quarter performance, reporting revenue of $823 million, a 14% year-over-year increase, and adjusted earnings per share of $2.38, surpassing analysts' estimates of $2.25. The growth was driven by sustained demand across preclinical research, drug safety testing, and bioanalytical services, with the company's global clinical development segment recording a 20% revenue uptick. CRL's continued investment in infrastructure and talent enabled it to maintain high utilization rates and expand its client base, including major biopharma firms in North America and Europe. The company's underlying strength underscores the growing reliance of pharmaceutical and biotech firms on external partners for complex, time-sensitive drug development. Despite macroeconomic headwinds and rising R&D costs, outsourcing demand remained resilient, with CRL securing several new long-term contracts and expanding its footprint in emerging markets. The firm’s backlog reached $920 million, up 12% from the prior year, reflecting strong forward visibility. CRL's performance contributed to broader healthcare sector momentum, with the XLP ETF (XLV) gaining 1.6% on the day and the Biotechnology ETF (BME) rising 1.9%. Investors interpreted the results as a sign of sector-wide stability and growth potential, particularly in services critical to the drug development pipeline. The stock rose 5.4% in after-hours trading, signaling strong market confidence in CRL’s execution and market positioning. Looking ahead, CRL reaffirmed its full-year guidance, projecting 2026 revenue between $3.25 billion and $3.30 billion, with adjusted EPS in the range of $9.10 to $9.30. The company cited ongoing innovation in non-clinical development services and strategic expansions in Asia-Pacific and Latin America as key growth drivers.